PfRH5-induced human monoclonal antibodies show broadly neutralizing activity in P. falciparum clinical isolates

Vaccines to the Plasmodium falciparum reticulocyte binding-like protein homolog 5 (PfRH5) target the blood stage of the parasite’s life cycle. PfRH5 has the potential to trigger the production of strain-transcendent antibodies and has proven its efficacy both in pre-clinical and early clinical studies. Vaccine-induced monoclonal antibodies (mAbs) to PfRH5 showed promising outcomes in cultured P. falciparum strains from distinct geographic areas. Here, we assessed the functional impact of vaccine-induced mAbs to PfRH5 on the genetically more complex P. falciparum clinical isolates. We used mAbs isolated from single-cell sorted B-cells of volunteers enrolled in the phase 1a (NCT02181088) clinical trial of the viral-vectored PfRH5 vaccine and used ex-vivo growth inhibition assays (GIA) to assess their efficacy in P. falciparum clinical isolates. Next-generation sequencing (NGS) was used to assess the breadth of genetic diversity in P. falciparum clinical isolates and to infer the genotype/..., Monoclonal antibody production
The generation of the mAbs used here has previously been described. Briefly, the variable heavy and light chains of the antibody-producing genes were amplified from single-cell-sorted plasmablasts isolated from peripheral blood mononuclear cells (PBMCs) of vaccinees from the first-in-human viral-vectored PfRH5 vaccine trial (NCT02181088). Cognate, paired heavy and light chains were cloned into separate human IgG vectors and transformed into E. coli Mix & go competent cells. The panel of mAbs used in this study included earlier well-characterized human-vaccine-induced antibodies (R5.001, R5.004, R5.007, R5.008, R5.011, R5.016 and R5.017) as well as two chimeric mAbs (c2AC7 and c9AD4). These mAbs were expressed by transfection of Expi293F cells with paired plasmids encoding matched heavy and light chains using the ExpiFectamine 293 (Invitrogen) reagents and purified from culture supernatants using a protein G column. Purified antibodies were subsequently..., , # PfRH5-induced human monoclonal antibodies show broadly neutralizing activity in *P. falciparum* clinical isolates

[https://doi.org/10.5061/dryad.8931zcrzv](https://doi.org/10.5061/dryad.8931zcrzv)

The data contains growth inhibition assay data (reported as percent inhibition relative to isotype control) for all antibodies used in the study. The data is organized by tab by antibody and a codebook is included preceding the following tabs for each analysis type. There are three main analyses for which data is included: 1) RH5 Antibody GIA, which gives the percent GIA for each anti-RH5 monoclonal antibody (c2AC7, c9AD4, R5.016, R5.017, R5.004, R5.008, R5.011, R5.007, R5.001); 2) RH5 Antibody Comb GIA, which gives the percent GIA for individual and combinations of anti-RH5 monoclonal antibodies (R5.011 + R5.001; R5.011 + R5.007; R5.011 + R5.008); and 3) BSG Antibody GIA, which gives the percent GIA for anti-BSG monoclonal antibody (MEM-M6_6)

## Description of the data and file structure...,